ArticleParasites & vectors2026
Integrated transcriptomic and proteomic analysis of cancer-suppressive Mesocestoides corti larvae.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe larvae of Mesocestoides corti have been previously shown to abrogate the growth and metastasis of the highly aggressive B16F10 melanoma in mice. In order to investigate the potential ways in which this effect is mediated, we present, to the best of our knowledge, the most comprehensive analyses of M. corti larval molecular data so far, while listing and exploring various potentially immunomodulatory molecules found therein. We show expression and protein abundance in larvae under in vivo and in vitro conditions. A promising ortholog, M. corti Kunitz-type chymotrypsin-specific inhibitor 1 (McKI-C1) of a known cancer-suppressive Kunitz protein from Echinococcus granulosus is also tested, both in vitro and in vivo.
methodsIn order to explore the potential effector mechanisms and molecules behind its cancer-suppressive capabilities, we analyzed the M. corti larval transcriptome in the C57BL/6J and ICR mouse strains, as well as in vitro. The proteomic profiles of whole homogenate and excretory-secretory products of tetrathyridia were analyzed by nano-shotgun liquid chromatography with tandem mass spectrometry and thoroughly annotated. A Kunitz protein candidate (McKI-C1) was recombinantly expressed in Escherichia coli, biochemically characterized, and functionally tested for its anti-cancer effect with mouse melanoma B16F10 cells and mouse ovarian carcinoma ID8 cells.
resultsWe present, to the best of our knowledge, the most extensive list of experimentally verified M. corti protein products. Many proteins potentially responsible for this tapeworm's immune-related cancer-suppressive abilities and immunomodulation were found within its proteome and transcriptome. These include numerous members of the superfamily of cysteine-rich secretory proteins, such as glioma pathogenesis-related-like proteins, and Kunitz-domain proteins. Functional tests of recombinant McKI-C1 performed both in vitro and in vivo did not confirm its expected tumor-suppressing properties. Therefore, the exact effectors of this tapeworm's likely immune-mediated anti-tumor capabilities need to be examined in further studies.
conclusionsThe transcriptomic and proteomic analysis of M. corti larvae carried out in the present study produced an extensive list of promising immunomodulatory or cancer-suppressive molecules. While the molecule chosen for analysis in the present study, McKI-C1, did not show any effect in vitro or in vivo, the immunomodulatory or cancer-suppressive potential of the other experimentally verified molecules remains of interest.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.